Tesaro — Q4 2015 Earnings Presentation
22 slides from Tesaro's earnings presentation, Feb 25, 2016
Slide 1: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private S
Slide 2: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 3: 2015 Was a Pivotal Year for TESARO
2015 Was a Pivotal Year for TESARO Key Accomplishments Established Field Organization Launched 1st Commercial Product Advanced Product Pipeline Expanded Executive Team Full-scale, experienced oncology sales team and corporate accounts teams Medical science liaison, nurse educator teams A valuable as
Slide 4: VARUBI: TESARO's First Marketed Product
Approved by FDA on September 1, 2015 1 Provides protection from CINV for the full delayed risk period (25–120 hours) 2 Single oral dose administration just prior to chemotherapy 6 Included in NCCN® Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus for MEC and HEC 3 No dose adju
Slide 5: Strategy to Drive Growth
Strategy to Drive Growth VARUBI®: Establish Oral, Take Share Establish IV, Take Share Grow NK-1 Market Opportunity Each Initial VARUBI Dose May Lead to An Additional Three to Four Doses During an Average Course of Chemotherapy Year 1 Year 2 Year 3 Year 4 Volume Oral IV
Slide 6: Commercial Launch Update: The First Weeks
Commercial Launch Update: The First 10 Weeks Data as of January 31, 2016; IOD: In-office dispensing; RA: receptor antagonist 1 Source: Company estimates; wholesaler and specialty pharmacy data 2 Source: IMS DDD data analysis and Company estimates 3 Source: Managed Markets Insight & Technology, LLC a
Slide 7: Tim Pearson, Chief Financial Officer
Tim Pearson Chief Financial Officer
Slide 8: Q4 2015 Financial Results
Q4 2015 Financial Results Unless otherwise noted, figures are in thousands, except for per-share data. Three Months Ended December 31, 2014 Three Months Ended December 31, 2015 License Revenue -- $230 Expenses: Cost of Sales -- $268 Research & Development $29,814 42,852 Selling, General & Administra
Slide 9: Mary Lynne Hedley, Ph.D., President & Chief Operating Officer
Mary Lynne Hedley, Ph.D. President & Chief Operating Officer
Slide 10: A Balanced Portfolio of Product Candidates
A Balanced Portfolio of Product Candidates mAb: Monoclonal antibody * In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups ** In collaboration with the Hoosier Cancer Research Network *** In collaboration with SARC, the Sarcoma Alliance for Research through C
Slide 11: Development Programs Update
Development Programs Update Bioequivalence trial successfully achieved its primary endpoint Planned clinical development program is complete NDA preparations on track to support submission in Q1 2016 Anticipate a 12-month FDA review Rolapitant IV Patient treatment continues in the Phase 3 NOVA trial
Slide 12: Development Programs Update
Development Programs Update Bioequivalence trial successfully achieved its primary endpoint Planned clinical development program is complete NDA preparations on track to support submission in Q1 2016 Anticipate a 12-month FDA review Rolapitant IV Patient treatment continues in the Phase 3 NOVA trial
Slide 13: NOVA Trial: Study Data Anticipated in Q2
Phase 3 NOVA Trial NOVA Study Data Anticipated in Q2 Prospectively defined statistical analysis of PFS in the HRD population >90% power PFS: Progression free survival; HRD: Homologous recombination deficiency gBRCAmut Endpoint Assessment Niraparib 300 mg Placebo Non-gBRCAmut / HRD Endpoint Assessmen
Slide 14: Phase 3 Trials in Recurrent Platinum Sensitive Ovarian Cancer Support NOVA Assumptions
Median PFS in chemotherapy-free maintenance period is < 6 months Phase 3 Trials in Recurrent Platinum Sensitive Ovarian Cancer Support NOVA Assumptions *Maintenance Period initiates ~6w post discontinuation of chemotherapy (6 x 21day cycles) Source: ICON4, CALYPSO, AGO-OVAR 2.5 and OCEANS trials. Ad
Slide 15: Additional Monotherapy and Combination Trials
Additional Monotherapy and Combination Trials NIRAPARIB: QUADRA trial of niraparib for ovarian cancer treatment PRIMA trial of niraparib for first line ovarian cancer BRAVO trial of niraparib for patients with gBRCAmut advanced/metastatic breast cancer treatment Niraparib + bevacizumab (AVANOVA) com
Slide 16: Development Programs Update
Development Programs Update NDA: New Drug Application IND: Investigational New Drug application mAb: Monoclonal Antibody IV: Intravenous I-O: Immuno-oncology Bioequivalence trial successfully achieved its primary endpoint Planned clinical development program is complete NDA preparations on track to
Slide 17: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 18: Strong Financial and Strategic Position
Strong Financial and Strategic Position TESARO: First Commercial Product Launched Portfolio Addresses Large Markets Balanced Product Pipeline Strong Financial Position Proven Management Team CINV: >$1B Ovarian: $4B Breast: $1B Several Programs, Early to Late Stage, Small Molecules & Biologics ~$230M
Slide 19: TESARO: 2016 Goals
T E S A R O : 2016 Goals Continue to execute on the U.S. VARUBI commercial launch Submit the NDA for IV rolapitant in Q1 2016 Submit the oral rolapitant MAA to the EMA in Q2 2016 VARUBI® (rolapitant) Initiate enrollment in the PRIMA trial in Q1 2016 Initiate enrollment in the niraparib/KEYTRUDA® com
Slide 20: TESARO 2016 Goals
TESARO 2016 Goals > Continue to execute on the U.S. VARUBI commercial launch > Submit the NDA for IV rolapitant in Q1 2016 > Submit the oral rolapitant MAA to the EMA in Q2 2016 VARUBI® (rolapitant) > Initiate enrollment in the PRIMA trial in Q1 2016 > Initiate enrollment in the niraparib/KEYTRUDA®
Slide 21: Fourth-Quarter 2015 Results
Fourth-Quarter 2015 Results February 25, 2016
Slide 22: TESARO Fourth-Quarter 2015 Results
w TESARO Fourth-Quarter 2015 Results February 25, 2016